Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

15 May 2009

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gene expression and cancer classification
Share to Genomic variations and chromosomal abnormalities
Share to HER2/EGFR in Cancer Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 19448591
DOI: 10.1038/modpathol.2009.78

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare eventPMID 19448591Read ↗

Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplificationSemantic proximity Read ↗

Polysomy 17 in Breast Cancer: Clinicopathologic Significance and Impact on HER-2 TestingSemantic proximity Read ↗

Polysomy 17 and HER-2 Amplification: True, True, and UnrelatedSemantic proximity Read ↗

HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Semantic proximity Read ↗

Poor prognostic significance of unamplified chromosome 17 polysomy in invasive breast carcinomaSemantic proximity Read ↗

Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17.Semantic proximity Read ↗

The important molecular markers on chromosome 17 and their clinical impact in breast cancer.Semantic proximity Read ↗

The complexity of genotypic alterations underlying HER2-positive breast cancer: an explanation for its clinical heterogeneity.Semantic proximity Read ↗

Aneusomy 17 in Breast Cancer: Its Role in HER-2/neu Protein Expression and Implication for Clinical Assessment of HER-2/neu StatusSemantic proximity Read ↗

Clinical array-based karyotyping of breast cancer with equivocal HER2 status resolves gene copy number and reveals chromosome 17 complexitySemantic proximity Read ↗

Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort studySemantic proximity Read ↗

Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.